MARK1 - New-wiki

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	CCR6	C-C motif chemokine receptor 6	Beta defensins Chemokine receptors bind chemokines G alpha (i) signalling events
Novel	ESRRG	estrogen related receptor gamma	Nuclear Receptor transcription pathway	Troglitazone Diethylstilbestrol Tamoxifen Cholic Acid Afimoxifene 4-HYDROXY-N'-(4-ISOPROPYLBENZYL)BENZOHYDRAZIDE p-Cumylphenol Bisphenol A Bisphenol Z Estradiol acetate Estradiol benzoate Estradiol cypionate Estradiol dienanthate Estradiol valerate
Novel	KCNK2	potassium two pore domain channel subfamily K member 2	TWIK related potassium channel (TREK) Phase 4 - resting membrane potential	Dofetilide Dronedarone
Novel	NIBAN1	niban apoptosis regulator 1
Novel	TGFB2	transforming growth factor beta 2	Platelet degranulation Molecules associated with elastic fibres TGF-beta receptor signaling activates SMADs ECM proteoglycans TGFBR3 regulates TGF-beta signaling	Trabedersen	Graft-versus-host disease Allograft rejection
Novel	USH2A	usherin			Usher syndrome (US) Retinitis pigmentosa (RP)
	CCDC102B	coiled-coil domain containing 102B
	GJA5	gap junction protein alpha 5	Gap junction assembly		Atrial fibrillation
	INCA1	inhibitor of CDK, cyclin A1 interacting protein 1
	MAP2	microtubule associated protein 2		Estramustine Paclitaxel Docetaxel
	MAP4	microtubule associated protein 4		Paclitaxel Docetaxel Artenimol
	MAPT	microtubule associated protein tau	Caspase-mediated cleavage of cytoskeletal proteins	Lansoprazole Astemizole Paclitaxel Docetaxel Flortaucipir F-18	Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3) Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
	STK11	serine/threonine kinase 11	AMPK inhibits chREBP transcriptional activation activity Energy dependent regulation of mTOR by LKB1-AMPK Regulation of TP53 Activity through Phosphorylation FOXO-mediated transcription of cell death genes		Peutz-Jeghers syndrome Pancreatic cancer
	TAOK1	TAO kinase 1	Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion RHO GTPases Activate Formins Mitotic Prometaphase EML4 and NUDC in mitotic spindle formation	Fostamatinib
	TCL1B	TCL1 family AKT coactivator B
	TFAP2A	transcription factor AP-2 alpha	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors Negative regulation of activity of TFAP2 (AP-2) family transcription factors Negative regulation of activity of TFAP2 (AP-2) family transcription factors TFAP2 (AP-2) family regulates transcription of other transcription factors Activation of the TFAP2 (AP-2) family of transcription factors TFAP2 (AP-2) family regulates transcription of growth factors and their receptors TFAP2 (AP-2) family regulates transcription of cell cycle factors TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation Positive Regulation of CDH1 Gene Transcription Regulation of MITF-M-dependent genes involved in pigmentation Specification of the neural plate border Specification of the neural plate border Developmental Lineage of Mammary Stem Cells		Branchiooculofacial syndrome (BOFS)
	YAF2	YY1 associated factor 2	RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known Transcriptional Regulation by E2F6

Search Results for: MARK1